Scaling up a bioprocess from lab to production fundamentally alters physical properties like oxygen transfer (KLA). This change in physics, not necessarily a procedural mistake, is often the root cause of failure at scale, leading to different cell growth and product quality.

Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

Unlike many biologics that can be scaled exponentially, membrane proteins often have inherent expression limitations. This means that scaling up production is a linear, rather than exponential, process. This fundamental constraint directly impacts CMC strategy, facility planning, and the overall cost of goods for therapies relying on these complex proteins.

Scaling from a T-flask to a bioreactor isn't just increasing volume; it's a fundamental shift in the biological context. Changes in cell density, mass transfer, and mechanical stress rewire cell signaling. Therefore, understanding and respecting the cell's biology must be the primary design input for successful scale-up.

Downstream purification processes can be modified and optimized throughout a product's lifecycle. However, the cell line selection is effectively permanent once the master cell bank is created. Choosing a non-robust cell line, such as one highly sensitive to minor pH shifts, will create persistent manufacturing challenges for the lifetime of the product.

For live cell therapies, the manufacturing process fundamentally shapes the biological product. Teams often rush to scale production, focusing on yield and cost. Instead, they should first fully understand how the process impacts cell potency and function to avoid effectively scaling the wrong biology.

A common error is screening strains or media in a simple batch mode when the final process will be fed-batch. This mismatch leads to incorrect candidate ranking and selection, forcing teams to restart the development process once the error becomes apparent during scale-up.

The challenge of scaling 3D cell cultures isn't just about building larger systems. A more fundamental problem is the inability to measure and characterize the complex 3D environment in real-time. Without effective in-process analytics to ensure quality control and process optimization, true industrial scalability remains unachievable.

Low-productivity R&D systems, like HEK cells, can hide product-related impurities such as truncated forms. These impurities are often at levels too low to detect. When the process is scaled up using high-productivity CHO cells, these once-invisible impurities can become a major issue, impacting yield and product quality.